22.01.2020 | Cannomed raised approx. NIS 27 million with a 40% discount; Manor Gindi and Kfir Gindi are represented by our firm
Further to articles advertized and posted on our firm’s website over the last month, Cannomed raised approx. NIS 27 million with a 40% discount with the assistance of Manor Gindi and Kfir Gindi.
Shareholders in BioPharm, who invested NIS 3 million, will receive approx. 13% of the company’s capital • BioPharm will be merged into Cannomed for 50% of the shares and following the merger, BioPharm owners – the Gindi brothers and Hagit Weinstock and Dudu Zehavi – approx. 57% of the merged company.
Manor Gindi and Kfir Gindi were represented in the transaction by Adv. Tomer Altman, partner and Head of Securities Practice and Adv. Rachel Zilberfarb-Schreiber from the Commercial Department.
The translation was executed courtesy of Tomedes Translations